Release Details

Publication of a shareholder newsletter

Paris, October 4^th, 2016 -  ABIVAX (Euronext Paris : FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today announces the publication of a shareholder newsletter that provides an update on the major achievements of the first half of 2016. The Shareholder Newsletter is available on the website at: www.abivax.com (Investors and Investor Presentation).